Historical Press Releases:
The press releases posted on this Site are current only as of their
date. Nventa Biopharmaceuticals does not update its press releases solely due to
a change in the facts described in old press releases. Old press
releases are provided only to give readers a sense of past developments
and should not be taken as implying that the information contained
in them remains accurate.
Press Releases 2001
December
20, 2001
  Stressgen
Biotechnologies Closes $27.8 Million Bought Deal Financing
December
18, 2001
HspE7
Potentially Eliminates the Need for Surgical Intervention and Improves
the Quality of Life in Anal Dysplasia Patients
December
3 , 2001
Stressgen
Biotechnologies Announces $25 Million Bought Deal Financing
November
29 , 2001
Stressgen
Announces Robust HPV Data from Multiple Phase II Clinical Trials
November
27 , 2001
Stressgen
Conference Call Notification Thursday, Nov 29, 2001 - 8:30 AM EST:
5:30 AM PST - on New Phase II Data for HspE7
November
19 , 2001
Stressgen
Biotechnologies Initiates Phase II Recurrent Respiratory Papillomatosis
Trial in Children
October
25, 2001
Stressgen
Biotechnologies Reports Third-Quarter 2001 Results
October
24, 2001
Stressgen
adds New Member to Board to Strengthen Clinical and Regulatory Expertise
for the Advancement of HspE7 to Commercialization
October
10, 2001
Stressgen
Conference Call Notification, Thursday, October 25, 2001 4:00
p.m. ET; 1:00 p.m. PT - 3Q 2001 Results
September
4, 2001
Stressgen
Presents Positive HspE7 Data that 71% of High Grade Anal Dysplasia
Patients Treated May Avoid Surgery
August 2, 2001
Stressgen
Biotechnologies Reports Second Quarter 2001 Financial Results
August 1, 2001
Stressgen
Completes Early Enrollment in its Phase III Trial for HspE7 for
Anal Dysplasia Caused by HPV: Company Previously Announced Early
Enrollment in its Phase II Genital Warts Trial
July 20, 2001
Stressgen
Conference Call Notification Thursday, August 2, 2001 - 4:00 p.m.
ET; 1:00 p.m. PT
June 6, 2001
Stressgen
Preliminary Clinical Data Demonstrate Robust Activity for HspE7
in Genital Warts
June 1, 2001
Stressgen
Conference Call Notification
May 3, 2001
Stressgen
Biotechnologies Announces First Quarter 2001 Financial Results
April 24, 2001
Stressgen
Presents New Data Indicating The Majority Of Anal Dysplasia Patients
Improve with HspE7
April 17, 2001
Stressgen
Targets Hepatitis B as the Next Hsp Fusion Program
April 10, 2001
Stressgen's Genital Warts Program
Ahead of Schedule Due to Early Completion of Patient Enrollment
in Phase II Trial
March 29, 2001
Stressgen's HspE7 Receives Orphan Drug Status for Recurrent Respiratory
Papillomatosis
March 8, 2001
Stressgen Biotechnologies Announces 2000 Financial Results
March 5, 2001
Stressgen Appoints Donald D. Tartre
as Vice President and Chief Financial Officer and Company Opens
San Diego Office and Renews Lease for Victoria Research Facility
January 9, 2001
Stressgen Initiates Phase II Genital Warts
Trial
|
